- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15:12 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 25 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 19.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | 132 | GlobeNewswire (Europe) | Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 05.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 137 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen | |
| 02.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 05.11.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing | 160 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new... ► Artikel lesen | |
| 30.10.25 | CERo Therapeutics denied Nasdaq listing, seeks OTC markets | 23 | Seeking Alpha | ||
| 30.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Receipt of Nasdaq Panel Determination | 662 | GlobeNewswire (Europe) | Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC... ► Artikel lesen | |
| 21.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML | 247 | GlobeNewswire (Europe) | Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 16.10.25 | Cero Therapeutics passt Kaufvertrag an und sichert sich 2,25 Mio. US-Dollar im ersten Closing | 4 | Investing.com Deutsch | ||
| 15.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.10.25 | CERo Therapeutics completes first cohort in AML clinical trial | 2 | Investing.com | ||
| 13.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML | 210 | GlobeNewswire (Europe) | Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published... ► Artikel lesen | |
| 10.10.25 | CERo Therapeutics open to takeover offers as it awaits key data - Axios | 9 | Investing.com | ||
| 10.10.25 | CERo Therapeutics signalisiert vor wichtigen Studiendaten Verkaufsbereitschaft | 2 | Investing.com Deutsch | ||
| 22.09.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,836 | +2,93 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,672 | +4,02 % | Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) | ||
| CAPRICOR | 22,650 | +1,12 % | Capricor +727%: Biotech-Tipp schlägt heftig ein! | Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Dank eines gigantischen Multibagger-Kursfeuerwerks sorgt mein Biotech-Tipp aus dem Juli für glückselige Follower.... ► Artikel lesen | |
| CORMEDIX | 9,500 | -1,55 % | CorMedix, Inc.: CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance | - Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million - Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million - FY 2025 Pro Forma Net Revenue Guidance Raised... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,460 | -6,99 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| REPLIMUNE | 7,650 | +5,52 % | Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months | ||
| VALERIO THERAPEUTICS | 0,135 | -3,57 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,395 | 0,00 % | Rani Therapeutics ändert Satzung, reduziert Stimmrechte und beendet Steuerabkommen | ||
| IO BIOTECH | 0,649 | +1,45 % | IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights | Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 15,710 | +4,28 % | Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating | ||
| OSR HOLDINGS | 0,623 | +3,90 % | OSR Holdings Inc.: Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings | Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university
... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 22,940 | +43,38 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,720 | +36,52 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen |
Das Unternehmen CERO THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,095 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.